NCT05917158View on ClinicalTrials.gov

A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 23, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
CarcinomaUpper Tract Urothelial CarcinomaUTUC
Interventions
DRUG

RC48-ADC and JS001

Patients in group will receive 6 x 3 week cycles of RC48-ADC (Disitamab Vedotin) 2mg/kg in combination with JS001 (Toripalimab) 3mg/kg intravenously, followed by toripalimab (3 mg/kg) every 3 weeks for up to 1 year.

Trial Locations (1)

210000

RECRUITING

Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, Nanjing

All Listed Sponsors
lead

Jinling Hospital, China

OTHER